Uncategorized
AVEO announces research agreement with Ophthotech
AVEO Oncology has entered into a research and exclusive option agreement with Ophthotech, according to a press release.The agreement provides Ophthotech with an exclusive license outside of Asia to examine the potential of AVEO’s tivozanib, a small-molecule VEGF tyrosine kinase inhibitor, for the potential treatment of non-oncologic diseases of the eye.Under the agreement, Ophthotech is obligated to pay AVEO an upfront option fee of $500,000.